Free Trial
NASDAQ:CRDL

Cardiol Therapeutics Q4 2025 Earnings Results & Report

Cardiol Therapeutics logo
$0.98 -0.02 (-2.10%)
Closing price 03:59 PM Eastern
Extended Trading
$0.98 +0.01 (+0.61%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardiol Therapeutics beat analyst earnings expectations in its Q4 2025 results, released March 30, 2026. The company reported EPS of -$0.05 versus the -$0.09 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
7:00 AM ET

Cardiol Therapeutics EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.09
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Cardiol Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Cardiol Therapeutics Q4 2025 Earnings FAQ

Cardiol Therapeutics (NASDAQ:CRDL) reported earnings of -$0.05 per share for Q4 2025, beating the consensus estimate of -$0.09. The report was announced on Monday, March 30, 2026.

Cardiol Therapeutics Earnings Headlines

A $247 tool for $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
See More Cardiol Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiol Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiol Therapeutics and other key companies, straight to your email.

About Cardiol Therapeutics

Cardiol Therapeutics (NASDAQ:CRDL) is a Canadian biotechnology company developing therapies for inflammatory heart disease and other cardiovascular conditions. Its research focuses on treatments intended to address inflammation and related damage to the heart.

The company’s lead candidate, CardiolRx, is a pharmaceutical-grade cannabidiol formulation under clinical investigation for conditions including myocarditis and pericarditis. Cardiol also has CRD-38, an investigational candidate being studied for potential use in heart failure. These candidates are experimental and are not approved medicines.

View Cardiol Therapeutics Profile